Kymera Therapeutics Inc
KYMR61.260USD
+2.600+4.43%
收盘 11/10, 16:00（美东）报价延迟15分钟
4.39B总市值
亏损市盈率 TTM
关于 Kymera Therapeutics Inc 公司
Kymera Therapeutics, Inc. 是一家生物制药公司。该公司专注于发现和开发新型小分子疗法，通过利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白质。该公司的靶向蛋白质降解 (TPD) 平台（称为 Pegasus）使其能够发现具有针对全身致病蛋白质活性的高选择性小分子蛋白质降解剂。该公司利用其 Pegasus 平台设计专注于免疫炎症和肿瘤学领域的新型蛋白质降解剂，并继续将其平台的功能应用于其他治疗领域。其临床阶段项目是 IRAK4、STAT3 和 MDM2，它们各自针对生物学上已证实的途径中的高影响目标，为治疗一系列免疫炎症疾病、血液系统恶性肿瘤和/或实体瘤提供了机会。
Kymera Therapeutics Inc简介
公司代码KYMR
公司名称Kymera Therapeutics Inc
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
员工数量188
证券类型Ordinary Share
年结日Aug 21
公司地址500 North Beacon Street, 4Th Floor
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话18572855314
网址https://www.kymeratx.com/
公司代码KYMR
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
Kymera Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
-14.83%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
-14.83%
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
47.07M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 9月29日 周一
更新时间: 9月29日 周一
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Associates, Inc.
9.45%
Baker Bros. Advisors LP
9.24%
Avoro Capital Advisors LLC
9.11%
BVF Partners L.P.
7.65%
Fidelity Management & Research Company LLC
7.55%
其他
56.99%
持股股东
持股股东
占比
T. Rowe Price Associates, Inc.
9.45%
Baker Bros. Advisors LP
9.24%
Avoro Capital Advisors LLC
9.11%
BVF Partners L.P.
7.65%
Fidelity Management & Research Company LLC
7.55%
其他
56.99%
股东类型
持股股东
占比
Investment Advisor
46.31%
Investment Advisor/Hedge Fund
30.56%
Hedge Fund
25.30%
Venture Capital
7.94%
Individual Investor
1.42%
Corporation
1.07%
Research Firm
0.76%
Private Equity
0.69%
Bank and Trust
0.35%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
423
80.49M
111.88%
+1.59M
2025Q2
394
76.16M
108.56%
+417.04K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
2023Q2
349
61.24M
110.72%
-7.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Associates, Inc.
6.80M
9.51%
+153.96K
+2.32%
Jun 30, 2025
Baker Bros. Advisors LP
6.65M
9.3%
+655.50K
+10.93%
Jun 30, 2025
Avoro Capital Advisors LLC
6.56M
9.17%
+95.56K
+1.48%
Jun 30, 2025
BVF Partners L.P.
5.50M
7.7%
+340.91K
+6.60%
Jun 30, 2025
Fidelity Management & Research Company LLC
5.43M
7.6%
+1.02M
+23.20%
Jun 30, 2025
The Vanguard Group, Inc.
5.61M
7.85%
+386.91K
+7.41%
Jun 30, 2025
Wellington Management Company, LLP
5.37M
7.51%
-624.81K
-10.42%
Jun 30, 2025
Atlas Venture
4.90M
6.85%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.52M
4.92%
-109.70K
-3.02%
Jun 30, 2025
Invus Public Equities Advisors, LLC
3.43M
4.79%
+187.84K
+5.80%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
Harbor Human Capital Factor US Small Cap ETF
1.21%
SPDR S&P Biotech ETF
0.99%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Direxion Daily S&P Biotech Bull 3X Shares
0.57%
First Trust Small Cap Growth AlphaDEX Fund
0.48%
First Trust Multi-Manager Small Cap Opportunities ETF
0.44%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.41%
iShares Biotechnology ETF
0.32%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.4%
Harbor Human Capital Factor US Small Cap ETF
占比1.21%
SPDR S&P Biotech ETF
占比0.99%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.57%
First Trust Small Cap Growth AlphaDEX Fund
占比0.48%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.44%
ProShares Ultra Nasdaq Biotechnology
占比0.42%
Invesco Nasdaq Biotechnology ETF
占比0.41%
iShares Biotechnology ETF
占比0.32%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
